We bring you the latest news from the healthcare about the health care in the United Kingdom.

maandag 15 oktober 2018

British Journal of Cancer - Table of Contents alert Volume  119 Issue 7

British Journal of Cancer

TABLE OF CONTENTS

Volume 119, Issue 7

In this issue
Editorial
Review Article
Article
Correspondence
Also new
AOP

Editorial

Are we inadvertently widening the disparity gap in pursuit of precision oncology?

Daniel E. Spratt

British Journal of Cancer 2018 119 :783 - 784; August 21, 2018; 10.1038/s41416-018-0223-6

Abstract | Full Text

Review Article

The colorectal cancer epidemic: challenges and opportunities for primary, secondary and tertiary prevention

Hermann Brenner & Chen Chen

British Journal of Cancer 2018 119 :785 - 792; October 04, 2018; 10.1038/s41416-018-0264-x

Abstract | Full Text

Article

25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial

Astrid Lipplaa, Ricardo Fernandes, Andrea Marshall, Paul Lorigan, Janet Dunn et al.

British Journal of Cancer 2018 119 :793 - 800; July 23, 2018; 10.1038/s41416-018-0179-6

Abstract | Full Text

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy

Tracy L. Rose, David D. Chism, Ajjai S. Alva, Allison M. Deal, Susan J. Maygarden et al.

British Journal of Cancer 2018 119 :801 - 807; October 08, 2018; 10.1038/s41416-018-0229-0

Abstract | Full Text

Independent validation of the PREDICT breast cancer prognosis prediction tool in 45,789 patients using Scottish Cancer Registry data

Ewan Gray, Joachim Marti, David H. Brewster, Jeremy C. Wyatt & Peter S. Hall

British Journal of Cancer 2018 119 :808 - 814; September 17, 2018; 10.1038/s41416-018-0256-x

Abstract | Full Text

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

Sarah P. Blagden, Ivana Rizzuto, Puvan Suppiah, Daniel O'Shea, Markand Patel et al.

British Journal of Cancer 2018 119 :815 - 822; September 12, 2018; 10.1038/s41416-018-0244-1

Abstract | Full Text

Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer

Ping Wang, Viktor Magdolen, Christof Seidl, Julia Dorn, Enken Drecoll et al.

British Journal of Cancer 2018 119 :823 - 831; October 05, 2018; 10.1038/s41416-018-0260-1

Abstract | Full Text

Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences

Dinja T. Kruger, Karin J. Beelen, Mark Opdam, Joyce Sanders, Vincent van der Noort et al.

British Journal of Cancer 2018 119 :832 - 839; October 05, 2018; 10.1038/s41416-018-0221-8

Abstract | Full Text

A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis

Elin Sjöberg, Magnus Frödin, John Lövrot, Artur Mezheyeuski, Martin Johansson et al.

British Journal of Cancer 2018 119 :840 - 846; October 08, 2018; 10.1038/s41416-018-0266-8

Abstract | Full Text

Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism

Riikka Johanna Niemi, Elena Ioana Braicu, Hagen Kulbe, Kaisa Maria Koistinen, Jalid Sehouli et al.

British Journal of Cancer 2018 119 :847 - 854; October 08, 2018; 10.1038/s41416-018-0270-z

Abstract | Full Text

Analysis of cell proliferation and tissue remodelling uncovers a KLF4 activity score associated with poor prognosis in colorectal cancer

Silvia Halim, Elke K. Markert & Alexei Vazquez

British Journal of Cancer 2018 119 :855 - 863; October 05, 2018; 10.1038/s41416-018-0253-0

Abstract | Full Text

Differences in DNA methylation profiles by histologic subtype of paediatric germ cell tumours: a report from the Children's Oncology Group

Lindsay A. Williams, Lauren Mills, Anthony J. Hooten, Erica Langer, Michelle Roesler et al.

British Journal of Cancer 2018 119 :864 - 872; October 05, 2018; 10.1038/s41416-018-0277-5

Abstract | Full Text

Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents

Malgorzata Bajor, Agata O. Zych, Agnieszka Graczyk-Jarzynka, Angelika Muchowicz, Malgorzata Firczuk et al.

British Journal of Cancer 2018 119 :873 - 884; October 05, 2018; 10.1038/s41416-018-0263-y

Abstract | Full Text

Characteristics of The Cancer Genome Atlas cases relative to U.S. general population cancer cases

Xiaoyan Wang, Joseph T. Steensma, Matthew H. Bailey, Qianxi Feng, Hannah Padda et al.

British Journal of Cancer 2018 119 :885 - 892; August 21, 2018; 10.1038/s41416-018-0140-8

Abstract | Full Text

Serially measured pre-diagnostic levels of serum cytokines and risk of brain cancer in active component military personnel

Alina V. Brenner, Peter D. Inskip, Jennifer Rusiecki, Charles S. Rabkin, Joshua Engels et al.

British Journal of Cancer 2018 119 :893 - 900; October 09, 2018; 10.1038/s41416-018-0272-x

Abstract | Full Text

Risk of diabetes after para-aortic radiation for testicular cancer

Harmke J. Groot, Jourik A. Gietema, Berthe M. P. Aleman, Luca Incrocci, Ronald de Wit et al.

British Journal of Cancer 2018 119 :901 - 907; October 09, 2018; 10.1038/s41416-018-0248-x

Abstract | Full Text

Correspondence

Comment on "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer"

Burak Uzunparmak & Ibrahim H. Sahin

British Journal of Cancer 2018 119 :908 - 908; October 09, 2018; 10.1038/s41416-018-0279-3

Abstract | Full Text

Reply to comment of "ERK and p38MAPK combine to improve survival in patients with BRAF mutant colorectal cancer"

Antonia K. Roseweir, Donald C. McMillan & Joanne Edwards

British Journal of Cancer 2018 119 :909 - 909; October 09, 2018; 10.1038/s41416-018-0275-7

Abstract | Full Text

Advertisement
Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription.

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to British Journal of Cancer. In order to do so, please purchase a subscription.

This email has been sent to dezorgsector.uk@gmail.com.

If you no longer wish to receive the email alerts from British Journal of Cancer click here to unsubscribe .
If you wish to discontinue all email services from Nature Research please click here to unsubscribe .

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved.

Springer Nature